Abstract:Background Elevated lipoprotein(a) is a well‐established risk factor for atherosclerotic vascular disease but is not measured in routine clinical care. Screening of high lipoprotein(a) in individuals with moderate elevations of low‐density lipoprotein cholesterol (LDL‐C) may identify individuals at high risk of cardiovascular disease. Methods and Results We examined 2606 Framingham Offspring participants (median age, 54 years; 45% men) prospectively with a median follow‐up of 15 years (n=392 incident cardiovascular events). Individuals with higher (≥100 nmol/L) versus lower lipoprotein(a) were divided into groups based on LDL‐C <135 mg/dL versus ≥135 mg/dL. In Cox models, after adjustment for known risk factors, high lipoprotein(a) (≥100 nmol/L) and LDL‐C ≥135 mg/dL were each significant predictors of cardiovascular disease (LDL‐C ≥135 mg/dL: hazard ratio [HR], 1.34; 95% CI, 1.09–1.64; P =0.006; high lipoprotein (a): HR, 1.31; 95% CI, 1.03–1.66; P =0.026). Across the groups of high/low lipoprotein (a) and LDL‐C ≥135 mg/dL or <135 mg/dL, the absolute cardiovascular disease risks at 15 years were 22.6% (high lipoprotein(a)/LDL‐C ≥135 mg/dL, n=248), 17.3% (low lipoprotein(a)/LDL‐C ≥135 mg/dL, n=758), 12.7% (high lipoprotein(a)/LDL‐C <135 mg/dL, n=275) and 11.5% (low lipoprotein(a)/LDL‐C <135 mg/dL, n=1328, reference group). Among individuals with LDL‐C ≥135 mg/dL, those with high lipoprotein(a) had a 43% higher risk (HR, 1.43; 95% CI, 1.05–1.97; P =0.02). Presence of high lipoprotein(a) with moderate LDL‐C levels (135–159 mg/dL) yielded absolute risks equivalent to those with LDL‐C ≥160 mg/dL (23.5%, 95% CI, 17.4%–31.3%; and 20.7%, 95% CI, 16.8%–25.3%, respectively). Conclusions Concomitant elevation of LDL‐C ≥135 mg/dL and lipoprotein(a) ≥100 nmol/L is associated with a high absolute risk of incident cardiovascular disease. lipoprotein(a) measurement in individuals with moderate elevations in LDL‐C, who do not otherwise meet criteria for statins, may identify individuals at high cardiovascular risk. Nonstandard Abbreviations and Acronyms CARDIoGRAMplusC4D Coronary Artery Disease Genome wide Replication and Meta analysis plus the Coronary Artery Disease Genetics CHARGE Cohorts for Heart and Aging Research in Genomic Epidemiology CVD cardiovascular disease FATS Familial Atherosclerosis Treatment Study FHS Framingham Heart Study LDL‐C low‐density lipoprotein cholesterol NRI net reclassification index Clinical Perspective What Is New? Individuals with both lipoprotein(a) ≥100 nmol/L and low‐density lipoprotein cholesterol ≥135 mg/dL represent a group at higher risk of developing cardiovascular disease. What Are the Clinical Implications? Measuring lipoprotein(a) may help stratify cardiovascular disease risk associated with moderate low‐density lipoprotein cholesterol, identifying individuals who may benefit from statin treatment. Elevated lipoprotein(a) is among the most common genetic dyslipidemias worldwide, affecting 1 in 5 individuals, and is an independent risk factor for cardiovascular disease (CVD). 1 , 2 Although evidence from Mendelian randomization supports a causal role of lipoprotein(a) in CVD, 3 , 4 limited therapeutic options exist to directly lower lipoprotein(a). 5 Current recommended strategies for management of individuals with high lipoprotein(a) emphasize the importance of managing other risk factors, including lowering elevated low‐density lipoprotein cholesterol (LDL‐C) concentrations, without much supporting evidence for such an approach. 6 , 7 , <a class="tab-link" href="# -Abstract Truncated-

Clinical Significance of Electronegative Low-Density Lipoprotein Cholesterol in Atherothrombosis

Predictive value of the relative lymphocyte count in coronary heart disease

Association Between Non-High-density Lipoprotein Cholesterol and Coronary Artery Disease in Patients with Acute Coronary Syndrome: a Single-Centre Retrospective Cross-Sectional Analysis

Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment

Electronegative Low-Density Lipoprotein L5 Induces Adipose Tissue Inflammation Associated With Metabolic Syndrome

Low-density lipoprotein electronegativity and risk of death after acute coronary syndromes: A case-cohort analysis

The LDL cumulative exposure hypothesis: evidence and practical applications

Comparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease

Small, Dense Low-Density Lipoprotein-Cholesterol and Atherosclerosis: Relationship and Therapeutic Strategies

Recent trends of low-density lipoprotein cholesterol control and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Taiwan: 2015-2020

Incremental Benefit of Lipid Lowering in a Large Chinese Population Aged 75 Years and Older With Established Atherosclerotic Cardiovascular Disease

[Distribution and Influencing Factors of Lipoprotein (a) Levels in Non-Arteriosclerotic Cardiovascular Disease Population in China].

Low-Density Lipoprotein Cholesterol 4: The Notable Risk Factor of Coronary Artery Disease Development

Lipoprotein (a) as a Biomarker for Cardiovascular Diseases and Potential New Therapies to Mitigate Risk

A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review

Non-HDL-c/TC: A Novel Lipid-Related Marker in the Assessment of Severity of Coronary Artery Lesions and Cardiovascular Outcomes.

Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart Study.

Relationship between small dense low density lipoprotein and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia

Molecular and Cellular Mechanisms of Electronegative Lipoproteins in Cardiovascular Diseases

Low-density lipoprotein particles in atherosclerosis